Results 151 to 160 of about 21,386 (303)

Oncogenic Mechanisms of Kaposi's Sarcoma‐Associated Herpesvirus on Cell Metabolism and Cell Transformation

open access: yesJournal of Medical Virology, Volume 97, Issue 8, August 2025.
ABSTRACT Kaposi's sarcoma‐associated herpesvirus (KSHV) is a human double‐stranded DNA virus that is responsible for the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and KSHV inflammatory cytokine syndrome (KICS).
Quanyuan Wan, Andrew J. Tucker, Jun Zhao
wiley   +1 more source

POEMS neuropathy: optimising diagnosis and management [PDF]

open access: yes, 2018
POEMS syndrome is a rare and disabling autoinflammatory condition characterised by a typical peripheral neuropathy and the presence of a monoclonal plasma cell disorder.
Carr, AS   +5 more
core   +1 more source

Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients

open access: yesTherapeutics and Clinical Risk Management, 2022
Dijiao Tang,1 Yuetong Guo,1 Yi Tang,2 Hongxu Wang1 1Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Department of Pathology, Chongqing Medical University, Chongqing,
Tang D, Guo Y, Tang Y, Wang H
doaj  

How and why systemic inflammation worsens quality of life in patients with advanced cancer [PDF]

open access: yes, 2017
Introduction: The presence of an innate host systemic inflammatory response has been reported to be a negative prognostic factor in a wide group of solid tumour types in both the operable and advanced setting, both local and distant.
Dolan, Ross D.   +4 more
core   +1 more source

Case report: Multicentric Castleman disease as a manifestation of immune reconstitution inflammatory syndrome in Malawi

open access: green, 2023
Matthew Painschab   +6 more
openalex   +1 more source

Sjögren's and plasma cell variant Castleman disease: a case report [PDF]

open access: yes, 2018
Castleman disease is a rare cause of lymphoid hyperplasia and may result in localized symptoms or an aggressive, multisystem disorder. It can mimic other diseases like lymphoma or tuberculosis.
Abrahams, Afua D   +4 more
core   +2 more sources

Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan

open access: yesModern Rheumatology, 2019
Objectives: To assess the clinicopathologic features of Multicentric Castleman disease (MCD) patients in Japan. Methods: We assessed baseline data for 342 Japanese MCD patients with a biopsy-proven diagnosis, enrolled in a prospective, observational ...
M. Murakami   +9 more
semanticscholar   +1 more source

A Rare Case of HHV-8 Associated Hemophagocytic Lymphohistiocytosis in a Stable HIV Patient

open access: yesCase Reports in Infectious Diseases, 2019
Background. Hemophagocytic lymphohistiocytosis (HLH) is a rare condition associated with viral infections including HIV. Cases have been reported mainly in advanced HIV/AIDS.
Nonso Osakwe   +3 more
doaj   +1 more source

Extracavitary tumor after primary effusion lymphoma: relapse or second distinct lymphoma?

open access: yesHaematologica, 2007
HHV-8-associated solid lymphomas which develop in extracavitary sites during the course of primary effusion lymphoma (PEL) could represent the relapse of original PEL tumors in different anatomical sites, or newly occurring distinct HHV-8-associated ...
Emmanuelle Boulanger   +6 more
doaj   +1 more source

Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data

open access: yesBritish Journal of Haematology, 2018
Siltuximab is the only US Food and Drug Administration‐approved treatment for idiopathic multicentric Castleman disease (iMCD), a rare haematological disorder associated with substantial morbidity and mortality.
D. E. Morra   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy